Compare Revvity Inc (RVTY) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Zeta Global Holdings Corp — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Zeta Global Holdings Corp trades at $33.09 (market cap $8.29B). The key difference: Revvity Inc is far larger — about 2× Zeta Global Holdings Corp's market cap, and Revvity Inc pays a 0.18% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Zeta Global Holdings Corp for 19 Days on average.
| RVTY | ZETA | |
|---|---|---|
Market Cap | $16.98B | $8.29B |
Volume | 1,456,900 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $157.36 | $33.74 |
52-Week Low | $82.26 | $14.55 |
Typical Hold Time | 12 Days | 19 Days |
Enterprise Value | $19.30B | $8.18B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
ZETA trades at $33.09, down 1.93% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and support at $32. Fundamentally, revenue grew to $1.3B in 2025 with a gross margin of 59.48%, but net income remains negative. Recent quarters saw EPS beats, and the company is expanding internationally with a new UK hub. Analyst sentiment is positive with 12 buy ratings and a $32.40 consensus target.
The outlook is cautiously optimistic due to strong revenue growth and AI-driven customer adoption, but profitability risks persist with negative net margins and high valuation multiples. Investors should weigh growth potential against execution risks and competitive pressures in the tech services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
